Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Inclusion Criteria

• •Adult males aged 18-35 years, with a body mass index (BMI) of 19-28 kg/m2.
• •Subjects who were healthy as determined by pre-study medical history, physical examination and 12-lead ECG.
• •Subjects who had clinical laboratory tests acceptable to the investigator.
• •Subjects who were negative for HbsAg, anti-HCV and HIV I and II tests at screening.
• •Subjects who were negative for drugs of abuse and alcohol tests at screening and admission.
• •Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day.
• •Subjects who were able and willing to give written informed consent.
• •Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders.
• •Subjects who had a clinically relevant surgical history.
• •Subjects who had a clinically relevant family history.
• •Subjects who had a history of relevant atopy.
• •Subjects who had a history of relevant drug hypersensitivity.
• •Subjects who had a history of alcoholism.
• •Subjects who had a history of drug abuse.
• •Subjects who consumed more than 28 units of alcohol a week.
• •Subjects who had a significant infection or known inflammatory process on screening and/or admission.
• •Subjects who had acute gastrointestinal symptoms at the time of screening and/or admission (e.g. nausea, vomiting, diarrhoea, heartburn).
• •Subjects who had an acute infection such as influenza at the time of screening and/or admission.
• •Subjects who had used prescription drugs within 4 weeks of first dosing.
• •Subjects who had used over the counter medication, excluding routine vitamins but including mega dose vitamin therapy, within one week of first dosing.
• •Subjects who had used any investigational drug and/or participated in any clinical trial within 3 months of their first admission to this study.
• •Subjects who had previously received BIA 3-202.
• •Subjects who had donated and/or received any blood or blood products within 3 months prior to screening.
• •Subjects who were vegetarians, vegans and/or had medical dietary restrictions.
• •Subjects who could not communicate reliably with the investigator.
• •Subjects who were unlikely to co-operate with the requirements of the study.
• •Subjects who were unwilling or unable to give written informed consent.